SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 203 filers reported holding SAGE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27 | -56.5% | 1,289 | -2.5% | 0.00% | -66.7% |
| Q2 2023 | $62 | +12.7% | 1,322 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $55 | +10.0% | 1,322 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $50 | -99.9% | 1,322 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $52,000 | +18.2% | 1,322 | -2.0% | 0.00% | +50.0% |
| Q2 2022 | $44,000 | -35.3% | 1,349 | -34.8% | 0.00% | -33.3% |
| Q1 2022 | $68,000 | -64.6% | 2,069 | -54.1% | 0.00% | -57.1% |
| Q4 2021 | $192,000 | -9.4% | 4,508 | -5.7% | 0.01% | -22.2% |
| Q3 2021 | $212,000 | -17.2% | 4,783 | +6.0% | 0.01% | -18.2% |
| Q2 2021 | $256,000 | -16.3% | 4,511 | +10.5% | 0.01% | -31.2% |
| Q1 2021 | $306,000 | -15.0% | 4,082 | -1.9% | 0.02% | -20.0% |
| Q4 2020 | $360,000 | -24.1% | 4,163 | -46.3% | 0.02% | -33.3% |
| Q3 2020 | $474,000 | +55.9% | 7,754 | +6.2% | 0.03% | +36.4% |
| Q2 2020 | $304,000 | +42.1% | 7,304 | -1.8% | 0.02% | +22.2% |
| Q1 2020 | $214,000 | +4.9% | 7,441 | +163.6% | 0.02% | +28.6% |
| Q4 2019 | $204,000 | – | 2,823 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |